Monday March 29, 2021 0 comments
BOULDER -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced the pricing of its underwritten initial public offering of 11,000,000 shares of its common stock at a public offering price of $16 per share.
The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “EWTX.” The offering is expected to close on March 30 subject to customary closing conditions.
All of the shares in the offering are being offered by Edgewise. The gross proceeds to Edgewise from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $176 million.
In addition, Edgewise has granted the underwriters a 30-day option to purchase up to 1,650,000 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Wedbush Securities Inc. is acting as co-manager for the offering.
Registration statements relating to the offering have been filed with the Securities and Exchange Commission. The offering is made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1115 Long Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204, or by email at [email protected]; Goldman Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 1-866-471-2526 or by emailing [email protected] or from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected].
Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.